Management of dyslipidemia in HIV-infected patients

Clinical Lipidology

Volumn 6, Issue 4, 2011, Pages 447-462

  Malvestutto, Carlos D ^b   Aberg, Judith A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drug interactions; fibrates; fish oil; guidelines; HIV associated dyslipidemia; hypertriglyceridemia; niacin; statins

Indexed keywords

ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BILE ACID SEQUESTRANT; DARUNAVIR; EFAVIRENZ; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NICOTINIC ACID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; STAVUDINE; TENOFOVIR; UNINDEXED DRUG;

AREA UNDER THE CURVE; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MITOCHONDRIAL TOXICITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY EFFECT; TREATMENT CONTRAINDICATION;

EID: 80051978397     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.25     Document Type: Review

References (118)

1. Friis-Moller N, Reiss P, Sabin C, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl J. Med. 356(17), 1723-1735 (2007) (Pubitemid 46658704)
2. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocr. Metabo. 74(5), 1045-1052 (1992)
3. Klein DHL, Quesenberry C, Silverberg M, Horberg M, Sidney S. Hospitalizations for CHD and MI among northern California HIV+ and HIV- men: changes in practice and Framingham risk scores. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006
4. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocr. Metab. 92(7), 2506-2512 (2007) (Pubitemid 47037350)
5. Obel N, Thomsen H, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin. Infect. Dis. 44(12), 1625-1631 (2007) (Pubitemid 46871511)
6. Saves M, Chene G, Ducimetire P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin. Infect. Dis. 37(2), 292-298 (2003) (Pubitemid 36930361)
7. Hsue P, Hunt P, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23(9), 1059-1067 (2009)
8. Tebas P, Henry W, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE 3(4), e2021 (2008)
9. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N. Engl J. Med. 340(1), 14-22 (1993)
10. Lorenz M, Markus H, Bots M, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4), 459-467 (2007) (Pubitemid 46184197)
11. Grunfeld C, Delaney JAC, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 23(14), 1841-1849 (2009)
12. Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 95(22), 1826-1835 (2009)
13. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 24(2), 243-253 (2010)
14. Hurley LLW, Xu L, Silverberg M, et al. Updated surveillance of cardiovascular event rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009
15. Lichtenstein KAC, Buchacz K, Moorman A, Wood K, Brooks J; HIV Outpatient Study Group. Analysis of cardiovascular risk factors in the HIV outpatient study cohort. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998) (Pubitemid 28213628)
17. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 256(20), 2823-2828 (1986) (Pubitemid 17178359)
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351-364 (1984)
19. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8-15 (1989) (Pubitemid 19043669)
20. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. American J. Cardiol. 86(9), 943-949 (2000)
21. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 115(4), 450-458 (2007) (Pubitemid 46184196)
22. Worm SKA, El-Sadr W, Kirk O, et al.; on behalf of the D:A:D Study Group. Triglycerides and the risk of myocardial infarction in the D:A:D study. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010
23. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 199(1), 79-86 (2008) (Pubitemid 351842701)
24. Mujawar Z, Rose H, Morrow M, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 4(11), E365-E365 (2006)
25. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289(22), 2978-2982 (2003) (Pubitemid 37430100)
26. Riddler S, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1- infected men in the multicenter AIDS cohort study. J. Acq. Imm. Defici. Synd. 48(3), 281-288 (2008)
27. Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 8(5), 280-287 (2007) (Pubitemid 46901526)
28. Hulgan T, Haubrich R, Riddler SA, et al. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142*. AIDS 25(1), 37-47 (2011)
29. Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top. HIV Med. 18(3), 112-118 (2010)
30. Phillips A, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivi. Therapy 13(2), 177-187 (2008) (Pubitemid 351535369)
31. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993-2000 (2009)
32. Kappelle PJWH, Gansevoort RT, Hillege JL, Wolffenbuttel BHR, Dullaart RPF. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J. Int. Med. 269(2), 232-242 (2011)
33. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, B92 (2009)
34. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 7(2), 85-98(2006)
35. Tarr P, Rotger M, Telenti A. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. Pharmacogenomics 11(4), 587-594 (2010)
36. Mahungu TW, Nair D, Smith CJ, et al. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. Clin. Pharmacol. Therapeutics 86(2), 204-211 (2009)
37. Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets J-B, Perret B. Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res. Human Retrovir. 24(2), 169-171 (2008) (Pubitemid 351282094)
38. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J. Infect. Dis. 189(6), 1056-1074 (2004) (Pubitemid 38373099)
39. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6(6), 421-425 (2005) (Pubitemid 41723310)
40. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acq. Imm. Defici. Synd. 47(2), 161-167 (2008) (Pubitemid 351172182)
41. Tomaka F, Lefebvre E, Sekar V, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med. 10(5), 318-327 (2009)
42. Overton TAJ, Gupta S, Ryan R, Baugh B, De La Rosa G. METABOLIK: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir. Presented at: 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 7-11 November 2010
43. Shikuma C, Yang Y, Glesby M, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J. Acquir. Immune Defic. Syndr. 44(5), 540-550 (2007) (Pubitemid 46594897)
44. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 1(1), e19 (2004)
45. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 23(17), 2289-2300 (2009)
46. Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 18(5), 815-817 (2004) (Pubitemid 38535012)
47. Jones C, Wilson I, Greenberg A, et al. Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J. Acq. Imm. Defici. Synd. 40(2), 202-211(2005) (Pubitemid 41395720)
48. Worm S, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201(3), 318-330 (2010)
49. Ribaudo H, Benson C, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: Short and long-term results from ACTG A5001/ALLRT. Clin. Infect. Dis. 52(7), 929-940 (2011)
50. Ding XA-C E, Cooper C, Miele P, Kornegay P, Soukup M, Marcus K. No association of myocardial infarction with ABC use: an FDA meta-analysis. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 27-March 2 2011 (Poster #808)
51. Satchell C, Cotter A, O'Connor E, et al. Platelet function and HIV: a case-control study. AIDS 24(5), 649-657 (2010)
52. Baum PKG, Galkina S, Stoddart C, Weiss E, Sullam P, McCune J. Abacavir, a competitive inhibitor of soluble guanylyl cyclase, increases platelet reactivity. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010
53. de Pablo COS, Peris S, Apostolova N, Esplugues J, Alvarez A. Abacavir induces human leukocyte endothelial cell interactions. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010
54. Hsue P, Hunt P, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23(15), 2021-2027 (2009)
55. Groups SIDADS. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22(14), F17-F24 (2008)
56. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin. Trials 10(1), 1-12 (2009)
57. Tungsiripat M, Kitch D, Glesby M, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24(11), 1781-1784 (2010)
58. Randell P, Jackson A, Zhong L, Yale K, Moyle G. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir. Therapy 15(2), 227-233 (2010)
59. Mir O, Garrabou G, Lpez S, et al. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir. Antivir. Therapy 11(5), 625-630 (2006) (Pubitemid 44277427)
60. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acq. Imm. Defici. Synd. 46(2), 125-133 (2007) (Pubitemid 47482607)
61. Arribas JR. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker]. Enferm. Infec. Microbiol. Clin. 26(Suppl. 11), 23-27 (2008)
62. Samaras K, Richardson R, Carr A. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. AIDS 24(11), 1727-1731 (2010)
63. Lennox J, Dejesus E, Berger D, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients. 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acq. Imm. Defici. Synd. 55(1), 39-48 (2010)
64. Rotger M, Bayard C, Taff P, et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Cir. Cardiovas. Genet. 2(6), 621-628 (2009)
65. Dube M, Stein J, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37(5), 613-627 (2003) (Pubitemid 37100800)
66. Law MG, Friis-Mller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med. 7(4), 218-230 (2006)
67. Friis-Moller N, Thibaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Euro. J. Cardiovas. Prevent. Rehabili. 17(5), 491-501 (2010)
68. Lundgren JD, Battegay M, Behrens G, et al. European AIDS clinical society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 9(2), 72-81 (2008) (Pubitemid 351232645)
69. Fichtenbaum C, Gerber J, Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 16(4), 569-577 (2002) (Pubitemid 34218852)
70. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Pat. Care STDs 14(1), 13-18 (2004)
71. Aberg J, Rosenkranz S, Fichtenbaum C, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG study A5108. AIDS 20(5), 725-729 (2006) (Pubitemid 43884300)
72. Aquilante CKJ, Anderson P, Christians U, et al. Influence of SLCO1B1 polymorphisms on pharmacokinetic (PK) variability in the drug-drug interaction between darunavir/ritonavir (DRV/r) and pravastatin (PRA). Presented at: 50th Interscience Conference on Antimicrobials and Chemotherapy. Boston, MA, USA, 12-15 September 2010
73. Prezista® (darunavir), package insert. Tibotec Inc., Beerse, Belgium
74. Livalo® (pitavastatin) package insert. Kowa Pharmaceuticals America Inc., AL, USA
75. Kiser J, Gerber J, Predhomme J, Wolfe P, Flynn D, Hoody D. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acq. Imm. Defici. Synd. 47(5), 570-578 (2008) (Pubitemid 351442013)
76. Busti A, Bain A, Hall R, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J. Cardiovas. Pharma. 51(6), 605-610 (2008)
77. Gerber J, Rosenkranz S, Fichtenbaum C, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J. Acq. Imm. Defici. Synd. 39(3), 307-312 (2005) (Pubitemid 40923210)
78. Grennan T, Walmsley S. Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. J. Int. Assoc. Physi. AIDS Care 8(6), 354-363 (2009)
79. van Luin M, Colbers A, van Ewijk-Beneken Kolmer EWJ, et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J. Acq. Imm. Defici. Synd. 55(1), 82-86 (2010)
80. Kiser J. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Curr. Opi. HIV AIDS 3(3), 330-341(2008)
81. Silverberg M, Leyden W, Hurley L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann. Int. Med. 150(5), 301-313 (2009)
82. Aberg J, Zackin R, Brobst S, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS clinical trials group study 5087. AIDS Res. Human Retrovir. 21(9), 757-767 (2005) (Pubitemid 41434180)
83. Wohl D, Waters D, Simpson R, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin. Infect. Dis. 47(8), 1105-1108 (2008)
84. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15(12), 1503-1508 (2001) (Pubitemid 32744597)
85. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 30(1), 26-31 (2003)
86. Fichtenbaum C, Yeh T-M, Evans S, Aberg J. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J. Clin. Lipidol. 4(4), 279-287 (2010)
87. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 24(1), 77-83 (2010)
88. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Cur. HIV Res. 6(6), 572-578 (2008)
89. Ridker P, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl J. Med. 359(21), 2195-2207 (2008)
90. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl J. Med. 358(14), 1431-1443 (2008) (Pubitemid 351482735)
91. Negredo E, Molt J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20(17), 2159-2164 (2006) (Pubitemid 44684706)
92. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 6, 15 (2007)
93. Chow D, Chen H, Glesby M, et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS 23(16), 2133-2141 (2009)
94. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16(16), 2195-2200 (2002) (Pubitemid 35387274)
95. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol. Metab. Clin. North Am. 38(1), 207-222 (2009)
96. Thomas JC, Lopes-Virella MF, Del Bene VE, et al. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharma 20(6), 727-734 (2000) (Pubitemid 30387690)
97. de Luis DA, Bachiller P, Aller R. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor. Nutrition 17(5), 414-415 (2001) (Pubitemid 32455546)
98. Caramelli B, de Bernoche CY, Sartori AM, et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz. J. Infect. Dis. 5(6), 332-338 (2001)
99. Palacios R, Santos J, Gonzlez M, et al. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J. Acq. Imm. Defici. Synd. 31(2), 251-253 (2003)
100. Badiou S, De Boever C, Dupuy A-M, Baillat V, Cristol J-P, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 172(2), 273-279 (2004) (Pubitemid 38167538)
101. Jacobson T. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 5(9), 507-518 (2009)
102. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb. Vasc. Biol. 23(2), 151-152 (2003) (Pubitemid 36231919)
103. Wohl D, Tien H-C, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41(10), 1498-1504 (2005) (Pubitemid 41579995)
104. De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acq. Imm. Defici. Synd. 44(3), 278-285 (2007) (Pubitemid 46328343)
105. Gerber J, Kitch D, Fichtenbaum C, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J. Acq. Imm. Defici. Synd. 47(4), 459-466 (2008) (Pubitemid 351366958)
106. Baril J-G, Kovacs C, Trottier S, et al. Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin. Trial 8(6), 400-411 (2007) (Pubitemid 350305214)
107. Dube M, Wu J, Aberg J, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivi. Therapy 11(8), 1081-1089 (2006) (Pubitemid 44955184)
108. Gerber M, Mondy K, Yarasheski K, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin. Infect. Dis. 39(3), 419-425 (2004) (Pubitemid 39050492)
109. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 8(4), 191-203 (2006) (Pubitemid 46138917)
110. Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J. Acq. Imm. Defici. Synd. 51(1), 29-36 (2009)
111. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin. Infect. Dis. 44(11), 1484-1492 (2007) (Pubitemid 46801594)
112. Madruga JRV, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1- infected patients: three-year follow-up after switching therapy. HIV Clin. Trials 8(6), 381-390 (2007) (Pubitemid 350305212)
113. Eron J, Young B, Cooper D, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 375(9712), 396-407 (2010)
114. Squires K, Pozniak A, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann. Inter. Med. 139(5), 313-320 (2003)
115. Martinez EAC, Antela A, Rivero A, et al. Effects of switching to ritonavir-boosted atazanavir on HIV-infected patients receiving antiretroviral therapy with hyperlipidemia. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005
116. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19(10), 1051-1058 (2005) (Pubitemid 40961145)
117. Grennan T, Walmsley S. Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. J. Int. Ass. Phys. AIDS Care 8(6), 354-363 (2009)
118. National Cholesterol Education Program. Third report on the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). 2002 (Update 2004) www.nhlbi.nih.gov/guidelines/ cholesterol/atp3full.pdf (Accessed 29 November 2010)